We provide implants, surgical instruments and AI-enabled software for spine fusion surgery.  We are currently focused on lumbar spine surgery.

Our aprevo technology platform consists of AI-enabled software solutions, interbody implants custom designed for each patient and single-use surgical instruments.

Note: Net loss and revenue are for the 12 months that ended March 31, 2025. 

(Note: Carlsmed, Inc. priced its IPO at $15.00 – the mid-point of its $14.00-to-$16.00 price range – and sold all 6.7 million shares – the number in the prospectus – to raise $100.5 million on Tuesday night, July 22, 2025. Background: Carlsmed disclosed its IPO’s terms in its S-1/A filing on July 15, 2025, as follows: Carlsmed is offering 6.7 million shares at a price range of $14.00 to $16.00 to raise $100.5 million, if priced at the $15.00 mid-point of its range. Background: Carlsmed, Inc. filed its S-1 to go public on June 26, 2025, without disclosing the terms for its IPO. Estimated initial IPO proceeds were $100 million, a placeholder figure.)